SCHEMBL31270644

SCHEMBL31270644

CCCCc1nc2cnc3ccsc3c2n1CC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.41
ADORA2B P29275 4/20 0.41
FEN1 P39748 1/20 0.39
USP7 Q93009 1/20 0.39
GLS O94925 1/20 0.39
TP53 P04637 1/20 0.38
THRB P10828 1/20 0.38
GPR119 Q8TDV5 5/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
FAAH O00519 1/20 0.38
MERTK Q12866 1/20 0.38
LMNA P02545 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25256593 1.00 ADORA2A (0.41) ADORA2AADORA2BFEN1USP7GLS
SCHEMBL25819366 0.90 ADORA2A (0.43) ADORA2AADORA2BFEN1USP7GPR119
SCHEMBL31270748 0.87 ADORA2B (0.41) ADORA2BGLSTP53THRBGPR119
SCHEMBL25262168 0.87 ADORA2B (0.41) ADORA2BGLSTP53THRBGPR119
SCHEMBL25819006 0.86 GLS (0.39) GLSGPR119FAAHMERTKLMNA
SCHEMBL31270623 0.86 GLS (0.39) GLSGPR119FAAHMERTKLMNA
SCHEMBL25257290 0.85 GRIN2B (0.47) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL31025935 0.85 GRIN2B (0.47) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL25818353 0.80 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL25301768 0.80 TLR7 (0.46) PDE4APDE4BPDE4CPDE4DPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055119-A9 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) 2026-02-26 US disclosed
US-20250257071-A9 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2025-08-14 US disclosed
US-20250002502-A1 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) 2025-01-02 US disclosed
EP-4458830-A1 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2024-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257071-A9 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF CYP11B2, CYP11B1, CYP3A5 ADORA2A 1834/4885ADORA2B 1831/4885FEN1 4208/4885
US-20260055119-A9 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF CYP11B1, CYP11B2, CYP2D6 ADORA2A 2615/4885ADORA2B 2385/4885FEN1 3630/4885
US-20250002502-A1 TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF CYP11B2, CYP11B1, CYP3A5 ADORA2A 1834/4885ADORA2B 1831/4885FEN1 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.